Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ephedra, Meth Precursors Focus Of State Legislation

This article was originally published in The Tan Sheet

Executive Summary

Several states are pushing through legislation to regulate over-the-counter drugs that may be illegally converted to methamphetamine.

You may also be interested in...

California ephedra

Latest state legislative action concerning ephedrine alkaloid-containing supplements would limit their sale to "behind-the-counter" status and require labeling warn consumers that exceeding the recommended dose may lead to "heart attack and stroke." SB 397, introduced March 12 by Assemblywoman Jackie Speier, a San Francisco-area Democrat, is similar to legislation introduced by Susan Davis last session. That measure was vetoed by Gov. Gray Davis Sept. 30. Susan Davis currently represents California's 49th district in the U.S. House; her former health staffer now works for Speier. SB 397 was read once and sent to the Committee on Health & Human Services. A hearing is scheduled for April 4

California Ephedrine Alkaloid Supplement Labeling Bill Veto Unexpected

California legislation requiring more stringent labeling for ephedrine-alkaloid dietary supplements was vetoed Sept. 30 by Gov. Gray Davis (D). The move came as a surprise to industry and to the office of Assemblywoman Susan Davis (D), who sponsored the bill.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts